Charles Rittershaus

Charles Rittershaus has over 20 years of work experience in the biotechnology industry. From 1998 to 2007, they worked at AVANT Immunotherapeutics as the Director of Discovery Research. During this time, they invented and led the development of a cholesterol management vaccine and also created a novel biologic glycoprotein with combined complement inhibitor and selectin ligand functions.

In 2008, Charles joined T2 Biosystems as a Principal Scientist. Charles developed intellectual property and expertise that enabled new Immuno and Molecular Diagnostics platform technologies utilizing Magnetic Resonance (T2Dx) and Hemostasis Diagnostics platform technologies utilizing Magnetic Resonance (T2Plex). Charles also led external collaborations to produce high affinity antibodies to small molecule therapeutic drugs. Charles continued their work at T2 Biosystems as an Independent Consultant starting in January 2017.

Charles Rittershaus earned a Bachelor's Degree in Biology/Immunology from the University of Massachusetts Lowell. However, no specific information about the start year, end year, or any other educational experiences prior to or following this degree is provided.